M
Marija Polovina
Researcher at University of Belgrade
Publications - 89
Citations - 2252
Marija Polovina is an academic researcher from University of Belgrade. The author has contributed to research in topics: Heart failure & Atrial fibrillation. The author has an hindex of 18, co-authored 77 publications receiving 1414 citations.
Papers
More filters
Journal ArticleDOI
Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology
Petar M. Seferovic,Mark C. Petrie,Gerasimos Filippatos,Stefan D. Anker,Giuseppe M.C. Rosano,Johann Bauersachs,Walter Paulus,Michel Komajda,Francesco Cosentino,Rudolf A. de Boer,Dimitrios Farmakis,Wolfram Doehner,Ekaterini Lambrinou,Yuri Lopatin,Massimo F Piepoli,Michael J. Theodorakis,Henrik Wiggers,John Lekakis,Alexandre Mebazaa,Mamas A. Mamas,Carsten Tschöpe,Arno W. Hoes,Jelena P. Seferovic,Jennifer Logue,Theresa McDonagh,Jillian P. Riley,Ivan Milinković,Marija Polovina,Dirk J. van Veldhuisen,Mitja Lainscak,Aldo P. Maggioni,Frank Ruschitzka,John J.V. McMurray +32 more
TL;DR: The coexistence of type 2 diabetes mellitus and heart failure (HF), either with reduced (HFrEF) or preserved ejection fraction (HFpEF), is frequent and associated with a higher risk of HF hospitalization, all‐cause and cardiovascular (CV) mortality.
Journal ArticleDOI
Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.
Petar M. Seferovic,Petar M. Seferovic,Marija Polovina,Johann Bauersachs,Michael Arad,Tuvia Ben Gal,Lars Lund,Stephan B. Felix,Eloisa Arbustini,Alida L.P. Caforio,Dimitrios Farmakis,Gerasimos Filippatos,Elias Gialafos,Vladimir Kanjuh,Gordana Krljanac,Giuseppe Limongelli,Aleš Linhart,Alexander R. Lyon,Ružica Maksimović,Davor Milicic,Ivan Milinković,Michel Noutsias,Ali Oto,Öztekin Oto,Sinisa U. Pavlovic,Massimo F Piepoli,Arsen D. Ristić,Giuseppe M.C. Rosano,Hubert Seggewiss,Milika Asanin,Jelena P. Seferovic,Jelena P. Seferovic,Frank Ruschitzka,Jelena Celutkiene,Tiny Jaarsma,Christian Mueller,Brenda Moura,Loreena Hill,Maurizio Volterrani,Yuri Lopatin,Marco Metra,Johannes Backs,Wilfried Mullens,Ovidiu Chioncel,Rudolf A. de Boer,Stefan D. Anker,Claudio Rapezzi,Andrew J.S. Coats,Andrew J.S. Coats,Carsten Tschöpe +49 more
TL;DR: E epidemiology, pathophysiology, natural history and latest developments in treatment of HF in patients with dilated (DCM), hypertrophic (HCM) and restrictive (RCM) cardiomyopathies are focused on.
Journal ArticleDOI
A 12-Year Follow-up Study of Patients With Newly Diagnosed Lone Atrial Fibrillation: Implications of Arrhythmia Progression on Prognosis: The Belgrade Atrial Fibrillation Study
Tatjana S. Potpara,Goran Stankovic,Branko Beleslin,Marija Polovina,Jelena M. Marinkovic,Miodrag Ostojic,Gregory Y.H. Lip +6 more
TL;DR: This 12-year follow-up study provides confirmatory evidence of a generally favorable prognosis of lone AF, but adverse outcomes (including stroke and thromboembolism) are significantly influenced by age and the (new) development of underlying heart disease.
Journal ArticleDOI
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure.
Petar M. Seferovic,Petar M. Seferovic,Andrew J.S. Coats,Piotr Ponikowski,Gerasimos Filippatos,Gerasimos Filippatos,Martin Huelsmann,Pardeep S. Jhund,Marija Polovina,Michel Komajda,Jelena P. Seferovic,Ibrahim Sari,Francesco Cosentino,Giuseppe Ambrosio,Marco Metra,Massimo F Piepoli,Ovidiu Chioncel,Lars Lund,Thomas Thum,Rudolf A. de Boer,Wilfried Mullens,Yuri Lopatin,Maurizio Volterrani,Loreena Hill,Johann Bauersachs,Alexander R. Lyon,Mark C. Petrie,Stefan D. Anker,Giuseppe M.C. Rosano +28 more
TL;DR: Type 2 diabetes mellitus is common in patients with heart failure (HF) and associated with considerable morbidity and mortality and there is evidence of several new glucose‐lowering medications showing either neutral or beneficial cardiovascular effects.
Journal ArticleDOI
Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.
Tatjana S. Potpara,Marija Polovina,Marina M. Licina,Jelena M. Marinkovic,Milica Prostran,Gregory Y.H. Lip +5 more
TL;DR: The CHA2DS2-VASc score reliably identified the “lone” AF patients who were at “truly low risk” forThromboembolism, and was the only tested risk stratification scheme with a significant predictive ability for thrombo Embolism among lone AF patients.